Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Valeant

Celgene building

Myeloma market set to be $9bn by 2021

New research shows it will pushed by a growing prevalence of the disease

- PMLiVE

Valeant swoops on Sprout to claim female sexual disorder drug

Comes in the same week that firm gained US approval for its ‘little pink pill’

- PMLiVE

US filing aims to elevate Brintellix above its competition

Drug looking for an edge in the highly competitive major depressive disorder market

Shire Basingstoke

Baxalta spells out opposition to Shire

Firm has rejected unsolicited $30bn bid from the Irish biopharma

- PMLiVE

Biomedical Catalyst funding ‘must continue’, says BIA

UKbiotech body warns against re-appearance of funding 'valley of death'

- PMLiVE

Shire makes shock $30bn bid for Baxalta

Irish firm seeking to buy the newly spun-out biotech that used to be part of Baxter

Shire Basingstoke

Shire buys into eyecare specialist

Will complement its investigational dry eye drug lifitegrast

RRD International hires Ulrich Thienel as CDMO

Company expands leadership team with former Takeda VP

- PMLiVE

Valeant buys Amoun Pharma for larger slice of MENA market

Comes after Canadian firm recently bought Salix for $11bn

- PMLiVE

J&J starts to feel biosimilar competition bite

Secondquarter Remicade sales outside the US dropped 26%

- PMLiVE

Takeda files ‘oral Velcade’ for myeloma in US

Follow up could be the first pill approved for this rare cancer

- PMLiVE

Adam Zaeske appointed as new MD of Takeda UK

Promoted after 11 years with the company

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links